{ "market" : {"NAME" : "U.S.", "ID" : "us_market", "TZ" : "ET", "TZOFFSET" : "-18000", "open" : "", "close" : "", "flags" : {"h" : "Thanksgiving Day"}} , "STREAMER_SERVER" : "http://streamerapi.finance.yahoo.com","arrowAsChangeSign" : false,"throttleInterval": "1000"}
zacks

Inspire Pharmaceuticals, Inc. (ISPH)

  • By Grant Zeng
  • On 1:00 am EST, Monday November 9, 2009

Inspire Pharmaceuticals, Inc. (NasdaqGM: ISPH - News) is a specialty pharmaceutical company focused on the development and commercialization of treatments for respiratory and ophthalmologic disorders.

Currently, the company has three products on the market and a robust pipeline. We see strong top line growth from 2009 and beyond. Inspire just reported positive phase III data of Denufosol for CF. The company has a strong collaborative alliance with Allergan Pharmaceuticals for key products that treat dry eyes and allergic conjunctivitis.

Current price is attractive. We maintain our Outperform rating on shares of Inspire with a price target of $7.00.

INSPIRE PHARMA (ISPH): Free Stock Analysis Report

Zacks Investment Research

ADVERTISEMENT

 Zacks Investment Research

Zacks Investment Research

FREE: 4 Stock Picks Every Day
This system triples the S&P 500.
Get Picks Now >>

 

 

Related Headlines

Related Blog Headlines

Top Stories

Related Message Boards

Sponsored Links

© 2009 Zacks.com. All rights reserved.